- $206.26m
- -$105.75m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 0.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.21% | ||
| Return on Equity | -50.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 19.95 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Directors
- Thomas Wiggans NEC (69)
- Douglas Love PRE (53)
- Jennifer Lew CFO (48)
- Sanjay Keswani EVP (51)
- Michael Overdorf EVP (51)
- Ted Yednock EVP (63)
- Larry Mattheakis CSO (63)
- Bettina Cockroft DRC
- William Waddill DRC
- William Carson IND (62)
- Jung Choi IND (51)
- Muneer Satter IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 3rd, 2011
- Public Since
- July 24th, 2020
- No. of Shareholders
- 28
- No. of Employees
- 100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 109,714,404
- Address
- 1400 SIERRA POINT PARKWAY, BRISBANE, 94005
- Web
- https://annexonbio.com/
- Phone
- +1 6508225500
- Auditors
- KPMG LLP
Upcoming Events for ANNX
Annexon Inc Annual Shareholders Meeting
Annexon Inc Annual Shareholders Meeting
Q2 2025 Annexon Inc Earnings Release
Similar to ANNX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Annexon share price?
As of Today at 19:15 UTC, shares in Annexon are trading at $1.88. This share price information is delayed by 15 minutes.
How has the Annexon share price performed this year?
Shares in Annexon last closed at $1.88 and the price had moved by -59.04% over the past 365 days. In terms of relative price strength the Annexon share price has underperformed the S&P500 Index by -62.19% over the past year.
What are the analyst and broker recommendations for Annexon?
The overall consensus recommendation for Annexon is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Annexon dividend yield?
Annexon does not currently pay a dividend.
Does Annexon pay a dividend?
Annexon does not currently pay a dividend.
When does Annexon next pay dividends?
Annexon does not currently pay a dividend.
How do I buy Annexon shares?
To buy shares in Annexon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Annexon?
As of the previous close price of $1.88, shares in Annexon had a market capitalisation of $206.26m.
Where are Annexon shares listed?
Here are the trading details for Annexon:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ANNX
What kind of share is Annexon?
Based on an overall assessment of its quality, value and momentum Annexon is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Annexon share price forecast for 2025?
The analyst consensus target price for shares in Annexon is $14.20. That is 655.32% above the last closing price of $1.88.
Analysts covering Annexon currently have a consensus Earnings Per Share (EPS) forecast of -$1.26 for the next financial year.
Find out moreWhat is the trend in the Annexon share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Annexon. Over the past six months, its share price has underperformed the S&P500 Index by -73.22%.
As of the last closing price of $1.88, shares in Annexon were trading -61.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Annexon PE Ratio?
The Annexon PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Annexon?
Annexon's management team is headed by:
- Thomas Wiggans - NEC
- Douglas Love - PRE
- Jennifer Lew - CFO
- Sanjay Keswani - EVP
- Michael Overdorf - EVP
- Ted Yednock - EVP
- Larry Mattheakis - CSO
- Bettina Cockroft - DRC
- William Waddill - DRC
- William Carson - IND
- Jung Choi - IND
- Muneer Satter - IND